Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 2. * Have previously untreated and histological examination confirms resectable stage II-IIIA/IIIB non-small cell lung cancer (according to the 8th edition of the AJCC TNM staging criteria), and the pathological type of squamous cell carcinoma and non-squamous cell carcinoma needs to be distinguished, and EGFR, ALK, and ROS1 should be negative for non-squamous non-small cell lung cancer * Adequate organ function and expected survival time ≥ 12 weeks; * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Key Exclusion Criteria: * Presence of mixed carcinoma component on histology. * Patients with other active malignancies within 5 years prior to enrollment. * Known active autoimmune diseases. * Currently participate in an interventional clinical study treatment or have been treated with another drug or investigational device within 4 weeks prior to the first dose. * Use of immunosuppressive agents within 14 days prior to the first dose of study treatment. * Presence of other uncontrolled serious medical conditions.